Equities

Kissei Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,275.00
  • Today's Change15.00 / 0.46%
  • Shares traded40.80k
  • 1 Year change+12.16%
  • Beta0.6044
Data delayed at least 20 minutes, as of Jul 17 2024 06:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.

  • Revenue in JPY (TTM)75.58bn
  • Net income in JPY11.16bn
  • Incorporated1946
  • Employees1.78k
  • Location
    Kissei Pharmaceutical Co Ltd19-48, YoshinoMATSUMOTO-SHI 399-8710JapanJPN
  • Phone+81 263259081
  • Fax+81 263257899
  • Websitehttps://www.kissei.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
JCR Pharmaceuticals Co Ltd42.87bn5.51bn82.35bn934.0014.461.419.431.9243.9243.92342.31450.130.43490.58913.2945,900,430.005.628.668.4713.4672.9074.5112.9218.241.2227.690.293230.6024.8313.1146.008.1918.5421.67
Torii Pharmaceutical Co Ltd56.28bn5.29bn109.87bn583.0020.290.900719.131.95188.05188.052,002.444,235.560.42882.722.2596,531,740.004.036.524.447.3544.8349.559.4017.985.58--0.0024.1711.74-2.674.4428.76-20.3820.11
Kyorin Pharmaceutical Co Ltd119.53bn5.32bn111.00bn2.04k18.640.759111.550.928692.7092.702,082.822,276.510.67591.342.6158,536,730.003.013.053.903.7943.0147.114.454.761.45--0.138967.745.531.0212.68-4.987.41-7.06
Zeria Pharmaceutical Co Ltd75.73bn7.73bn114.21bn1.78k12.261.197.491.51175.39175.391,717.901,806.330.53041.483.9942,614,000.005.393.898.396.2873.2971.9310.167.570.794611.750.373535.0910.744.1424.7817.4920.775.29
Mochida Pharmaceutical Co Ltd102.89bn4.55bn126.27bn1.52k26.680.933617.171.23126.33126.332,868.833,609.590.64781.863.2867,598,550.002.864.373.445.3150.6152.474.426.713.31--0.002945.16-0.3641-1.26-31.61-11.6310.91-1.21
Nxera Pharma Co Ltd16.43bn-9.07bn151.04bn350.00--2.28--9.19-107.30-107.30194.96736.600.1309--5.7746,954,280.00-7.23-0.6588-7.78-0.703674.4489.83-55.20-4.464.03-10.910.5238---18.00---1,982.98------
Towa Pharmaceutical Co Ltd227.93bn16.17bn157.38bn4.59k9.300.96464.620.6905328.58328.584,630.883,167.260.56841.513.7049,680,470.004.034.215.035.6335.7039.237.107.231.46--0.564921.019.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd75.58bn11.16bn160.51bn1.78k13.200.65410.332.12246.57246.571,669.954,977.430.31351.562.9442,483,980.004.683.615.053.9049.4149.4714.9412.694.43--0.007834.8711.980.89196.0015.286.5810.40
Sumitomo Pharma Co Ltd314.56bn-314.97bn163.93bn4.98k--1.05--0.5212-792.79-792.79791.76392.820.3081.214.0563,164,260.00-30.84-5.07-54.58-7.7359.7669.99-100.12-12.280.2992--0.7332---43.38-7.29-322.71--4.02--
KAKEN PHARMACEUTICAL CO., LTD.72.04bn8.03bn186.42bn1.14k19.071.0717.302.59212.76212.761,909.113,796.040.42642.053.4063,474,890.004.756.835.407.8753.4954.7811.1414.484.72--0.026151.25-1.29-5.2147.52-14.700.36390.00
Data as of Jul 17 2024. Currency figures normalised to Kissei Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

16.07%Per cent of shares held by top holders
HolderShares% Held
Brandes Investment Partners LPas of 15 May 20242.54m5.15%
The Vanguard Group, Inc.as of 04 Jul 20241.35m2.73%
Nomura Asset Management Co., Ltd.as of 31 May 20241.01m2.04%
Wellington Management Co. LLPas of 31 May 2024576.53k1.17%
Nikko Asset Management Co., Ltd.as of 05 Jul 2024484.90k0.98%
Daiwa Asset Management Co. Ltd.as of 31 May 2024458.30k0.93%
JPMorgan Asset Management (Japan) Ltd.as of 31 May 2024450.30k0.91%
Dimensional Fund Advisors LPas of 31 May 2024400.10k0.81%
BlackRock Fund Advisorsas of 03 Jul 2024385.70k0.78%
Norges Bank Investment Managementas of 31 Dec 2023273.30k0.55%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.